Vectra Cor
Medical Devices, 785 Totowa Rd, Totowa, New Jersey, 07512, United States, 11-50 Employees
Phone Number: +19*********
Who is VECTRACOR
VectraCor, Inc. is a medical device company with Disruptive Early Detection Technology in the Cardiology and Emergency Medicine marketplace with worldwide patents granted and over 40 publ...
Read More
-
Headquarters: 785 Totowa Rd, Totowa, New Jersey, 07512, United States
-
Date Founded: 2008
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
Brad Schreck
Email
Phone
Industry: Medical Devices
SIC Code: 3841; 3845; 5047
|
NAICS Code: 339112 |
Show More
VectraCor Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding VectraCor
Answer: VectraCor's headquarters are located at 785 Totowa Rd, Totowa, New Jersey, 07512, United States
Answer: VectraCor's phone number is +19*********
Answer: VectraCor's official website is https://vectracor.com
Answer: VectraCor's revenue is $5 Million to $10 Million
Answer: VectraCor's SIC: 3841; 3845; 5047
Answer: VectraCor's NAICS: 339112
Answer: VectraCor has 11-50 employees
Answer: VectraCor is in Medical Devices
Answer: VectraCor contact info: Phone number: +19********* Website: https://vectracor.com
Answer: VectraCor, Inc. is a medical device company with Disruptive Early Detection Technology in the Cardiology and Emergency Medicine marketplace with worldwide patents granted and over 40 published papers or abstracts. VectraCor is also the parent company of QRS Diagnostics, a manufacturer of PC-based, cardio-pulmonary devices including ECGs and Spirometers (Orbit Portable Spirometer). VectraCor has developed and patented a technology that will differentiate the current mature monitoring market by enhancing the cardiac monitor to incorporate more technology into one device from only 3 leads (5 electrodes). VectraCors technology incorporates the worlds first patented Cardiac Electrical Biomarker (CEB) for the real-time detection of ECG changes suggestive of an AMI. No other company has patented, developed and marketed a technology of this kind. The VectraplexECG System needs only 5 electrodes (Limbs and V2) to derive a 15-lead ECG in the US and 22 lead ECG in the EU (CE Mark). The VectraplexAMI will be displayed on the cardiac monitor as a number in real-time, in the same manner as the heart rate. VectraCor's VectraplexAMI index is displayed in real-time and may change if the patient unknowingly begins to develop ECG changes suggestive of an AMI, setting up an internal and audible alarm that can result in the display/print-out of the derived 12-22 lead ECG (15 leads in US and pending CE Mark for a derived 22 Lead ECG) and will prompt the user to acquire a standard 12 lead ECG (by adding the 5 additional electrodes from the same system) for interpretation by the physician.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month